Physician profile
Juri Kubes
NPI 1073302097
$850.02
in general payments reported to CMS, 2019-2025
21 companies · $850 in 2025
The $850 reported for 2025 was more than what 85% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $124.26 | 2025 | Enhertu, Tagrisso |
| Beone Medicines USA, INC. | $79.58 | 2025 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $65.29 | 2025 | Fruzaqla, Ninlaro |
| Incyte Corporation | $61.41 | 2025 | Monjuvi, Zynyz, Jakafi |
| Merck Sharp & Dohme LLC | $60.16 | 2025 | Keytruda, Welireg |
| Janssen Biotech, INC. | $52.88 | 2025 | Darzalex, Talvey, Rybrevant |
| Pfizer INC. | $52.79 | 2025 | |
| Genzyme Corporation | $39.54 | 2025 | |
| Sun Pharmaceutical Industries INC. | $32.70 | 2025 | |
| Springworks Therapeutics, INC. | $31.13 | 2025 | Gomekli |
| Bayer Healthcare Pharmaceuticals INC. | $30.48 | 2025 | |
| Alnylam Pharmaceuticals INC. | $26.81 | 2025 | Givlaari |
| Gilead Sciences, INC. | $25.82 | 2025 | Trodelvy |
| Puma Biotechnology, INC. | $25.80 | 2025 | |
| Glaxosmithkline, LLC. | $24.49 | 2025 | Ojjaara |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $23.13 | 2025 | Datroway |
| Abbvie INC. | $21.83 | 2025 | |
| Caris Mpi, INC. | $19.10 | 2025 | Mi Cancer Seek |
| Eisai INC. | $18.76 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.41 | 2025 | |
| Adaptive Biotechnologies Corporation | $16.65 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juri Kubes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.